ENDOCRINOLOGIST NATION

A SKIPTA COMMUNITY

Endocrinologist Nation by the Numbers

Engage with verified HCPs in Skipta’s online communities when they are focused on learning and collaborating with other NPIs within their own specialty or interest area.

Verified HCPs Reached

What are HCPs talking about?

Slide 6

Prescribing Decisions

What’s New in T2D? Highlights from the 2025 ADA Guidelines

We are at a privileged place in today's medical practice that we are able to look at comorbidities in our patients with T2DM and make choices for GLP-1RAs, SGLt2is with proven cardio-renal-metabolic benefits, self-management strategies and valuable information from CGMs.

Slide 3

Prescribing Decisions

Advancing T2D Management:
Key Insights from the Latest ADA Guidelines

I think CGMs have been the game changer for patients with diabetes in general - even those not on insulin. For diabetes patients on basal bolus insulin or are on a pump, and those who could meet criteria for being on a pump/ AID system - this is so much better, with hypoglycemia being prevented automatically and with overall better control. These systems are not fullproof and will be challenging to the patient who is used to having the ability to self correct multiple times on his/ her pump manually. The SGLT 2 inhibitors are excellent medications for DM - with benefits more multiple organ systems, but I believe GLP and GLP1/GIP meds offer even more benefits. Luckily they are not mutually exclusive and can be used together.

Slide 4

Patient Care

Advancing T2D Management:
Key Insights from the Latest ADA Guidelines

The addition of CGM has led to create a data collection for all patient specifically type one diabetics and elucidating times when they might be hypoglycemic another times they may be hypoglycemic, which is not shown by the typical hemoglobin A1c, which is attained every three months. These patients can use the CGM in order to track their meals, diets and result of their blood sugar secondary to the use of CGM. They just need greater coverage by all the insurance companies not just type one diabetics and not just patient we were taking insulin knows on oral therapy‘s benefit as well.

Slide 2

Patient Care

Lipid management: where are we falling short?

I prefer using statins initially and usually start with a moderate to high dose, then add ezetimibe or PCSK9 inhibitor. Coverage in my area is improving and most of my patients with type 2 diabetes or FH of a cardiac event are covered. Referral to a dietitian is also very important and I do believe that dietary restrictions can significantly improve LDLC.

ENDOCRINOLOGIST NATION

A SKIPTA COMMUNITY

Endocrinologist Nation by the Numbers

What are HCPs talking about?

Make your brand the heart of key HCP conversations, with customized, targeted brand messaging.